Wee1 Inhibitor ZN-c3 for Fallopian Tube Cancer

Phase < 1

Waitlist Available

Led By Evthokia Hobbs, M.D.

Research Sponsored by OHSU Knight Cancer Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day 1 to 30 days after last dose of study intervention

Awards & highlights

No Placebo-Only Group

Summary

This trial tests ZN-c3, a medicine that blocks enzymes needed for cancer cell growth, in patients with advanced or metastatic triple-negative breast cancer or ovarian cancer. By blocking an important enzyme, ZN-c3 aims to stop cancer cells from growing and spreading.

Eligible Conditions

Breast cancer
Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cancer
Peritoneal Carcinoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day 1 to 30 days after last dose of study intervention

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day 1 to 30 days after last dose of study intervention

This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 to 30 days after last dose of study intervention for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Incidence of adverse events

Percent decrease of phosphorylated CDK1 and/or Ki67, or p-HH3, or p-CHK1 in tumor cells

Secondary study objectives

CBR for ovarian cancer

Clinical benefit rate (CBR)

Overall survival

+2 more

Other study objectives

Cellular and molecular characteristics

ZN-c3 tumor and plasma concentrations

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (wee1 inhibitor ZN-c3)Experimental Treatment1 Intervention

Patients receive Wee1 inhibitor ZN-c3 PO QD on days 1-21. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

Do I qualify?Apply below to find out